Dr. Bellmunt on Immunotherapy Plus IDO in Urothelial Carcinoma – OncLive
OncLive |
Dr. Bellmunt on Immunotherapy Plus IDO in Urothelial Carcinoma
OncLive Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the combination of immunotherapy with IDO inhibitors for patients with urothelial carcinoma … |
